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Abstract
This study examined the mechanisms by which H2S modulates coronary microvascular resistance
and myocardial perfusion at rest and in response to cardiac ischemia. Experiments were conducted
in isolated coronary arteries and in open-chest anesthetized dogs. We found that the H2S substrate
L-cysteine (1-10 mM) did not alter coronary tone of isolated arteries in vitro or coronary blood
flow in vivo. In contrast, intracoronary (ic) H2S (0.1-3 mM) increased coronary flow from 0.49 ±
0.08 to 2.65 ± 0.13 ml/min/g (P□0.001). This increase in flow was unaffected by inhibition of Kv
channels with 4-aminopyridine (P=0.127) but was attenuated (0.23 ± 0.02 to 1.13 ± 0.13
ml/min/g) by the KATP channel antagonist glibenclamide (P□0.001). Inhibition of NO synthesis
(L-NAME) did not attenuate coronary responses to H2S. Immunohistochemistry revealed
expression of cystathionine gamma-lyase (CSE), an endogenous H2S enzyme, in myocardium.
Inhibition of CSE with β-cyano-L-alanine (10 µM) had no effect on baseline coronary flow or
responses to a 15 sec coronary occlusion (P=0.82). These findings demonstrate that exogenous
H2S induces potent, endothelial-independent dilation of the coronary microcirculation
predominantly through the activation of KATP channels, however, our data do not support a
functional role for endogenous H2S in the regulation of coronary microvascular resistance.
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Introduction
The endogenous gasotransmitter hydrogen sulfide (H2S) is known to exert a variety of
effects on the cardiovascular system (14, 37, 41). In particular, H2S has been shown to be a
vasodilator in multiple vascular beds (10, 17, 22, 39, 44, 45) and to influence the
physiologic regulation of vascular tone (15, 40) and blood pressure (44, 46). Other studies
have also demonstrated that H2S acts as a negative inotrope (14, 37, 41). Thus, H2S could
protect the heart from ischemic injury by mediating the balance between myocardial oxygen
delivery and metabolism. The potential cardioprotective actions of H2S are supported by
data indicating that exogenous administration of H2S donors protects against a loss of
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contractile function and diminishes myocardial infarct size/necrosis in animal models of
ischemia reperfusion injury (6, 19, 32, 47). Although these protective effects are associated
with improvements in coronary endothelial dependent and independent microvascular
reactivity (32), the direct effects of H2S on the coronary circulation have not been
specifically examined.
This investigation was designed to elucidate the mechanisms by which H2S influences
myocardial perfusion and to define the role of H2S in the regulation of coronary
microvascular resistance at rest and in response to a brief episode of cardiac ischemia.
Experiments tested the hypothesis that H2S induces dose-dependent coronary vasodilation
via endothelial-dependent production of nitric oxide (NO) (1, 11), and that endogenous
production of H2S contributes to the control of coronary blood flow in normal and/or
ischemic hearts. Additional studies were also conducted to examine whether H2S elicits
increases in coronary blood flow through activation of ATP-sensitive K+ (KATP) channels or
voltage-dependent K+ (Kv) channels, both of which have been shown to modulate vascular
responses to H2S in non-coronary vascular beds (28, 36, 45, 49) and in response to
myocardial ischemia (5, 7, 12). Findings from this investigation provide novel insight in to
the mechanisms and functional significance of H2S in the regulation of coronary blood flow
in vivo.
Methods
This investigation was approved by the IUPUI Institutional Animal Care and Use
Committee in accordance with the Guide for the Care and Use of Laboratory Animals (NIH
Pub. No. 85–23, Revised 1996). All animals studied were lean mongrel dogs weighing
between 20 and 30 kg. Following completion of experimental protocols, hearts were
fibrillated and excised as recommended by the American Veterinary Medical Association
Guide on Euthanasia (June 2007).
Immunohistochemistry
Immunohistochemical (IHC) analyses were performed in conjunction with Indiana
University Health Pathology Laboratory (Indianapolis, IN). Briefly, liver and cardiac tissues
were harvested immediately post mortem, rinsed in saline and transferred to 10% formalin.
Formalin fixed tissues were then exposed to primary IgG antibodies against cystathionine β-
synthase (CBS) and cystathionine γ-lyase (CSE) at manufacturer recommended
concentrations (Sigma Aldrich, St. Louis, Missouri). Slides were imaged at 10×
magnification on a Nikon Eclipse 80i microscope and images captured with a Nikon DS-Fi1
and associated Nikon Elements software.
Isometric tension studies
Canine hearts were excised upon sacrifice and the aorta cannulated to perfuse the coronary
tree with 4°C, Ca2+-free Krebs solution (131.5 mM NaCl, 5 mM KCl, 1.2 mM NaH2PO4,
1.2 mM MgCl2, 25 mM NaHCO3, 10 mM glucose) in order to rinse the excised heart of
blood and blood proteins. After perfusion, coronary arteries were grossly dissected from the
heart, and further isolated from surrounding myocardium and adventitia using a dissecting
Casalini et al. Page 2













microscope. Following adventitial removal, arteries were cut into 3 mm rings and mounted
in water-jacketed organ baths filled with a Ca2+-containing Krebs solution (131.5 mM NaCl,
5 mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 25 mM NaHCO3, 10 mM glucose, 4 mM
CaCl2) at 37°C. Optimal length (passive tension) was assessed by contractions of isolated
arteries to 60 mM KCl. Passive tension was increased in gram increments until there was
<10% change in active tension development to 60 mM KCl (typical optimal passive tension
equaled ~4 g). Once optimal passive tension was obtained, arteries were then pre-constricted
with 1 µM U46619 and stimulated with either NaHS (1-10 mM) or the H2S substrate L-
cysteine (1-10 mM). Changes in vascular tone were measured as a percent change from
maximal tension developed in response to 1 µM U46619.
Surgical preparation
Dogs were initially sedated with morphine (3 mg/kg, subcutaneously) and anesthetized with
α-chloralose (100 mg/kg, intravenously). The animals were then intubated and mechanically
ventilated (Harvard respirator) with oxygen-supplemented room air. A catheter was placed
into the thoracic aorta via the right femoral artery to measure aortic blood pressure and heart
rate. The left femoral artery was catheterized to supply blood to an extracorporeal perfusion
system used to perfuse the left anterior descending (LAD) artery at a controlled pressure
(100 mmHg). A catheter was also inserted into the right femoral vein for injection of
supplemental anesthetic, heparin and sodium bicarbonate. Arterial blood gases were
analyzed periodically throughout the experimental protocol and adjustments were made as
needed to maintain blood gas parameters within normal physiological limits. A left lateral
thoracotomy was performed to expose the heart, and the LAD was isolated distal to its first
major diagonal branch. Following heparin administration (500 U/kg, intravenously), the
LAD was cannulated with a stainless steel cannula connected to an extracorporeal perfusion
system. Coronary perfusion pressure (CPP) was regulated by a servo-controlled roller pump,
held constant at 100 mmHg. Coronary blood flow was continuously measured by an inline
Transonic Systems flow transducer (Ithaca, NY, USA). Data were continuously recorded on
IOX data acquisition software from Emka Technologies (Falls Church, VA, USA).
Experimental Protocol
Following coronary cannulation, hemodynamic parameters were allowed to stabilize for 30
min. Basal coronary blood flow and hematocrit were then determined, and based on these
parameters, an aqueous solution of NaHS was infused into the LAD perfusion line at
controlled rates in order to achieve coronary plasma NaHS concentrations of 100µM, 300
µM, 1 mM, and 3mM. Animals were also subjected to an L-cysteine dose response curve
(100 µM, 300 µM, 1 mM and 3 mM). Coronary flow responses as well as heart rate and
blood pressure were monitored throughout the course of the dose response curves.
Following a 15 min washout period, animals were then subjected to an identical NaHS dose
response curve in the presence of the NO synthase inhibitor L-NG-Nitroarginine methyl
ester (L-NAME, ~35 µg/ml, ic), the general Kv channel blocker 4-aminopyridine (4AP,
0.3mM, ic) or the KATP channel inhibitor glibenclamide (3mg/kg, iv). In a subset of animals
(n = 3), coronary reactive hyperemic responses were measured following a 15 second
occlusion of the LAD in the absence and presence of the CSE enzyme inhibitor β-cyano L-
alanine (BCA, 10µM, ic). Hyperemic responses were measured until coronary flow reached
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baseline values. All drugs (Sigma Aldrich, St Louis, MO, USA) with the exception of
glibenclamide (dissolved in equal parts of ethanol, propylene glycol, 1N NaOH) were
dissolved in saline and infused in to the coronary perfusion line. Data on the systemic
hemodynamic effects of each of these drugs are provided in Table 1.
Statistical analyses
Data are presented as mean ± SE. Statistical comparisons were made by a one-way or two-
way repeated measures analysis of variance (ANOVA) as appropriate (Sigma Plot 11.0
Software). If statistical differences (P < 0.05) in these analyses were noted, a Student-
Newman-Keuls multiple comparison test was performed. Reactive hyperemic volumes were
calculated as area under the curve using Prism software (GraphPad Software).
Results
Tissue Immunohistochemistry
Consistent with previous findings (2, 16), liver tissue sections stained positive for both of
the H2S producing enzymes cystathionine γ-lyase (CSE) (Figure 1A) and cystathionine β-
synthase (CBS) (Figure 1B). However, expression of these enzymes within liver vasculature
was relatively modest (see inset). Left ventricular myocardial tissue also stained positive for
CSE (Figure 1C) and CBS (Figure 1D). However, CSE and CBS were not prominently
expressed in the coronary vasculature (see inset).
Isometric Tension Studies
Isometric tension recordings were performed on isolated coronary artery rings pre-
constricted with the thromboxane A2 mimetic U46619 (1 µM). In these pre-contracted rings,
administration of the H2S substrate L-cysteine (1-10 mM; n = 3) tended to increase
isometric tension ~15% (Figure 2A) while NaHS (1-10 mM; n = 3) tended to diminish
active tension development ~5% (Figure 2B). However, neither L-cysteine (P = 0.27) nor
NaHS (P = 0.44) significantly altered coronary artery tension relative to U46619 treatment
alone.
Effects of H2S on Coronary Blood Flow In Vivo
Intracoronary administration of L-cysteine (0.1-3.0 mM) had no effect on baseline coronary
blood flow (Figure 2C). In contrast, infusion of NaHS (n = 5) dose-dependently increased
coronary blood flow from 0.49 ± 0.09 ml/min/g at baseline to 2.65 ± 0.15 ml/min/g at the
highest (3 mM) concentration of NaHS (Figure 2D; P < 0.001). This vasodilator response
was not significantly diminished by inhibition of NO synthase with L-NAME (Figure 3A; n
= 3) or by blockade of Kv channels with 4AP (Figure 3B; n = 3). However, administration
of the KATP channel antagonist glibenclamide significantly impaired coronary vasodilation
to 3mM H2S by ~ 70% (P < 0.001) (Figure 3B; n = 5).
Inhibition of H2S Producing Enzyme CSE
Administration of the CSE enzyme inhibitor BCA (10 µM; n = 3) had no effect on baseline
hemodynamic parameters (Table 1). The effect of CSE inhibition on the coronary blood
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flow response to a 15 sec coronary artery occlusion (i.e. coronary reactive hyperemia) is
shown in Figure 4. BCA did not significantly affect the reactive hyperemic response as
evidenced by no alterations in the peak vasodilatory response, flow volume of repayment or
in the repayment of the coronary flow debt following the inhibition of CSE (P = 0.82)
(Table 2).
Discussion
This study was designed to delineate the mechanisms by which H2S modulates coronary
microvascular resistance and myocardial perfusion at rest and in response to transient
cardiac ischemia. The major novel findings of the investigation include: 1) prominent
expression of the H2S producing enzymes CBS and CSE in canine myocardium; 2) infusion
of the key H2S substrate L-cysteine failed to significantly alter coronary vascular tone of
isolated conduit arteries in vitro or microvessels in vivo; 3) intracoronary administration of
H2S dose-dependently increases coronary blood flow (~ 5 fold) via activation of KATP
channels; 4) H2S mediated coronary vasodilation occurs independent of endothelial NO
production or Kv channel activation and is largely absent in conduit coronary arteries; 5)
inhibition of endogenous CSE has no effect on the regulation of coronary blood flow at rest
or in response to a brief coronary artery occlusion. Taken together, these findings indicate
that exogenous H2S induces potent dilation of the canine coronary microcirculation
predominantly through a KATP channel dependent (NO independent) mechanism. However,
our data support no functional role for endogenous H2S in the regulation of baseline
coronary resistance or ischemic coronary vasodilation.
Functional expression of H2S producing enzymes in canine hearts
Our IHC studies demonstrate the prominent expression the H2S producing enzymes (CBS
and CSE) in canine myocardium (Figure 1). This finding is consistent with other studies
which have documented the presence of CSE in rat and mouse liver and cardiac tissue (14,
16, 34, 46), and expression of CBS in rodent hearts (9, 35). IHC also revealed relatively low
levels of CSE and CBS expression in the liver and cardiac microcirculation (Figure 1C &
1D); which is consistent with little/no effect of the H2S substrate L-cysteine on tone of
isolated coronary arteries (Figure 2A) or on coronary blood flow in vivo (Figure 2C). This
lack of a coronary response to L-cysteine is in contrast with the recent findings of Leffler et
al. who documented dose-dependent dilation to L-cysteine in cerebral pial arterioles in
newborn swine (22); i.e. differences in the functional relevance of endogenous H2S
production likely exist between the cerebral and coronary circulation.
Although H2S is known to be a vasodilator in a variety of vascular beds (10, 17, 31, 36, 49),
primarily in the cerebral circulation (22, 23, 25, 26, 39), no study has directly examined
coronary vasodilation in response to NaHS administration in vivo. We found that NaHS
significantly increased coronary blood flow in a concentration dependent manner (Figure
2D). Interestingly, our findings indicate marked regional differences in coronary conduit vs.
microvascular responsiveness to H2S as isolated coronary arteries responded only ~5% to 3
mM NaHS while coronary flow increased ~500% in response to the same concentration of
NaHS.
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Mechanism of H2S-mediated coronary vasodilation
Earlier studies in peripheral arteries suggest that H2S mediated dilation occurs via an
endothelial-dependent mechanism (10, 48) that converges on the activation of smooth
muscle KATP (22, 25, 28, 29, 49, 50) and/or KCa channels (17, 26). However, the pathways
responsible for the effects of H2S in the coronary circulation have not been delineated. In the
current study, we found that intracoronary administration H2S (plasma concentration 3 mM)
induced an ~5-fold increase in coronary blood flow (Figure 2D). This increase in coronary
flow is not related to endothelial-production of NO as administration of the NOS inhibitor
L-NAME, at a dose we previously demonstrated to attenuate NO-mediated coronary
vasodilation in dogs (5, 20), did not diminish the coronary response to H2S (Figure 3A).
Infusion of the voltage-dependent K+ channel antagonist 4-aminopyridine (4AP) also had no
effect on H2S mediated coronary vasodilation (Figure 3B). However, inhibition of KATP
channels with glibenclamide significantly reduced the increase in coronary blood flow to
H2S by nearly 70% (Figure 3B). Therefore, our findings demonstrate that exogenous H2S
acts as a potent endothelial-independent vasodilator in the coronary circulation
predominantly via activation of smooth muscle KATP channels. Given the prominent role of
Kv and KATP channels in the regulation of coronary blood flow (3, 4, 13, 43), and the
relatively modest effect of KCa channel inhibition on coronary responses in vivo (7, 8, 21)
we elected to focus the present studies on H2S mediated activation of coronary Kv and KATP
channels. Since earlier studies in other vascular beds have documented a role for KCa
channels in H2S-induced dilation (18, 24, 27, 42), further systematic experiments are needed
to specifically examine the contribution of specific KCa channels (BKCa, IKCa, SKCa) to H2S
mediated increases in coronary blood flow.
Role of endogenous H2S in control of coronary blood flow
As outlined above, the lack of a coronary response to the H2S substrate L-cysteine (Figure
2) does not support an active role for endogenous H2S in the regulation of coronary
microvascular resistance. However, alterations in the physiologic state of the myocardium,
such as ischemia, have been shown to increase endogenous production of H2S and limit
myocardial ischemia-reperfusion injury (38). In order to examine the role of H2S in
ischemic coronary vasodilation, coronary reactive hyperemia studies were conducted in the
absence and presence of the CSE inhibitor BCA (30, 33). Findings from these experiments
indicate that 10 µM BCA, an effective dose capable of inhibiting liver H2S synthesizing
activity (30), had no effect on baseline coronary blood flow (Table 1) or on any aspect of
the coronary reactive hyperemic response (Figure 4); i.e. peak vasodilator response or the
overall debt to repayment ratio (Table 2). Therefore, although there is evidence to support a
role for endogenous H2S in mitigating myocardial ischemia-reperfusion injury (19, 32, 38,
51), there are little/no data to support that endogenous H2S is an active regulator of coronary
vasomotor tone at rest or following a brief episode of myocardial ischemia.
Conclusions
Findings from this investigation are the first to show that exogenous H2S induces potent,
endothelial NO-independent dilation of the canine coronary microcirculation, predominantly
through the activation of KATP channels. Despite the pronounced effects of exogenous H2S,
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our data do not support a functional role for endogenous H2S in the regulation of baseline
coronary resistance or ischemic coronary vasodilation. Such findings do not negate prior
studies regarding the cardioprotective effects of endogenous H2S in the ischemic heart (38),
but rather indicate that H2S-related improvements in cardiac function and ischemic injury
are not mediated by alterations in myocardial perfusion per se. Therefore, although
exogenous H2S demonstrates the capacity for robust coronary dilator responses, there was
no demonstrable physiologic role for H2S as a coronary signaling molecule in this study.
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Representative immunohistochemistry showing expression of the H2S producing enzyme
cystathionine γ-lyase (CSE) CSE in liver (A) and cardiac (C) tissue samples. Positive
staining for the H2S producing enzyme cystathionine β-synthase (CBS) in liver (B) and heart
(D). Insets: Magnification of microvessels show modest staining for both CSE and CBS in
liver and cardiac tissue samples.
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Representative isometric tension recordings show modest effects of L-cysteine (n=3) (A)
and NaHS (n=3) (B) on tension of isolated coronary artery rings pre-constricted with
U46619. In-vivo intracoronary infusion of L-cysteine had no effect on basal coronary blood
flow (C) while intracoronary infusion of NaHS significantly augmented coronary flow at
plasma concentrations >300 µM (D).
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Inhibition of NO synthase with L-Name produced a modest increase the coronary blood
flow response to intracoronary NaHS (n=3) (A). Coronary vasodilation to NaHS was
unaffected by the inhibition of voltage-dependent K+ channels with 4-AP (n=3) while
blockade of KATP channels with glibenclamide (n=5) markedly reduced NaHS-induced
dilation in the coronary circulation. # P < 0.05; * P < 0.001.
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Inhibition of the H2S producing enzyme cystathionine γ-lyase (CSE) with β-cyano-L-alanine
(BCA) (n=3) did not significantly alter the coronary blood flow response to a 15 sec
coronary artery occlusion.
Casalini et al. Page 14

























Casalini et al. Page 15
Table 1












Baseline 114 ± 6 74 ± 15 93 ± 8 99
± 26 0.47 ± 0.09
L-NAME 114 ± 6 79 ± 10 96 ± 7 95
± 16 0.50 ± 0.11
Baseline 112 ± 7 81 ± 15 96 ± 8 98
± 12 0.55 ± 0.15
4AP 107 ± 14 76 ± 13 90 ± 14 92 ± 10
0.34 ± 0.07
Baseline 107 ± 7 74 ± 8 89 ± 8 86
± 12 0.40 ± 0.04
Glibenclamide 122 ± 4* 90 ± 6* 103 ± 5* 78 ± 10
0.25 ± 0.03
Baseline 132 ± 15 90 ± 14 106 ± 14 79
± 24 0.27 ± 0.04
BCA 125 ± 17 83 ± 15 100 ± 16 90 ± 31
0.31 ± 0.04
Values are mean ± SE.
*indicates P < 0.05 vs. respective baseline. (L-NAME n = 3, 4AP n = 3, Glibenclamide n =5 , BCA n = 3).
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Table 2
Effect of CSE inhibition on the coronary blood flow response to a 15 sec coronary artery occlusion.
Control BCA
Peak Flow (ml/min/g) 1.33 ± 0.13 1.36 ± 0.11
Debt Area (ml/g) 0.09 ± 0.01 0.10 ± 0.02
Repayment Area (ml/g) 18.1 ± 1.8 18.2 ± 1.6
Repayment/debt Ratio (%) 359 ± 35 323 ± 48
Values are mean ± SE. (Control n = 3, BCA n = 3).
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